Grantham, Mayo, Van Otterloo & Co (GMO)’s Novo Nordisk NVO Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.03M	Sell	27,971 -157,000	-85%	-$7.44M	﹤0.01%	505
2025 Q4	$9.41M	Buy	184,971 +108,359	+141%	+$5.54M	0.02%	241
2025 Q3	$4.25M	Buy	76,612 +15,027	+24%	+$880K	0.01%	303
2025 Q2	$4.25M	Buy	61,585 +23,968	+64%	+$1.63M	0.01%	314
2025 Q1	$2.61M	Buy	+37,617	New	+$3.11M	0.01%	359
2019 Q3	–	Sell	-1,466,360	Closed	-$37.4M	–	771
2019 Q2	$37.4M	Sell	1,466,360 -887,200	-38%	-$21.9M	0.26%	67
2019 Q1	$61.6M	Buy	2,353,560 +351,600	+18%	+$8.64M	0.44%	48
2018 Q4	$46.1M	Buy	2,001,960 +34,200	+2%	+$760K	0.37%	54
2018 Q3	$46.4M	Buy	1,967,760 +604,706	+44%	+$14.8M	0.31%	64
2018 Q2	$31.4M	Buy	1,363,054 +49,054	+4%	+$1.17M	0.22%	68
2018 Q1	$32.4M	Buy	+1,314,000	New	+$34.5M	0.2%	82
2016 Q4	–	Sell	-123,400	Closed	-$2.57M	–	535
2016 Q3	$2.57M	Sell	123,400 -51,800	-30%	-$1.28M	0.01%	308
2016 Q2	$4.71M	Sell	175,200 -70,000	-29%	-$1.92M	0.02%	297
2016 Q1	$6.64M	Buy	+245,200	New	+$6.57M	0.02%	274

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s NVO Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Novo Nordisk (NVO) stake by 85% in Q1 2026, selling an estimated $7.44M and leaving 27,971 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #505.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NVO in Q1 2016 and has held it in 14 quarters since. The position peaked at $61.6M in Q1 2019. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) held 27,971 shares of Novo Nordisk worth $1.03M as of Q1 2026.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 157,000 Novo Nordisk shares in Q1 2026, an estimated $7.44M.
Novo Nordisk made up ﹤0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #505 holding.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Novo Nordisk in Q1 2016 and has held it in 14 quarters since.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Novo Nordisk position peaked at $61.6M in Q1 2019.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.